Health
GLP-1 Drugs Are Becoming More Than Weight Loss Medicine
Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025
Loading
Search
Results
17 stories for“obesity medicine”
Health
One Receptor, Two, or Three: Comparing Semaglutide, Tirzepatide and Retatrutide
Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.
Aug 11, 2026
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
The GLP-1 Era: How Weight-Loss Drugs Changed Us
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024
Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Health
Retatrutide Is Not Approved in Any Country. It Is Also for Sale in Most of Them
Lilly does not expect to file for approval until the first quarter of 2027. Search the drug's name today and you can have a vial by the weekend. The gap between those two facts is where the harm happens.
Aug 20, 2026
Health
A Tape Measure Round the Waist Did the Same Job as Four Measurements and a Formula
In 1,900 American adults, waist circumference on its own matched a new multi measurement framework against a proper body fat scan. BMI alone missed a substantial number of people who met the body fat criteria for obesity.
Sep 1, 2026
Health
Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
Health
Berberine and the 'Nature's Ozempic' Claim: What Evidence Shows
Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024
Health
Intermittent Fasting Works About as Well as Eating Less, Because in the Trials That Is What It Turned Out to Be
Three randomised trials put time-restricted eating against ordinary calorie control or against nothing. The eating window on its own did little. Combined with eating less, it did what eating less does. What that means for anyone considering it.
Sep 6, 2026
Health
Muscle Loss on GLP-1s: What the Evidence Really Shows
New body composition data compares lean mass loss on tirzepatide and semaglutide. Here is what is measured, and what remains unclear.
Jun 15, 2026
Health
Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
Health
Ozempic and Wegovy: What the Trials Actually Showed
Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024
Health
What Actually Happens When You Stop Taking a GLP-1
Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
May 15, 2024
Nutrition
A Healthy Diet Is Becoming a Luxury, and That Is a Public Policy Failure
The 2026 global food-security debate is shifting from calories alone to whether families can afford nutritious food. The consequences reach health, education and productivity.
Jul 31, 2026
Health
Loneliness Raises the Risk of Early Death by About a Quarter, and the World Health Organization Now Counts It as a Cause
A meta-analysis of seventy studies put the increased mortality risk from loneliness at 26 per cent and from living alone at 32 per cent. A WHO commission estimates 871,000 deaths a year. What the numbers mean, and what has been shown to help.
Aug 23, 2026
Latest Trends
Four Months After Its Founder Died, Nizam al-Tayyibat Is Bigger. That Is the Part Worth Studying.
Diaa al-Awady died on 19 April. Egypt banned his content on 3 May. The system spread faster afterwards. What that reveals about religious vocabulary, distrust of doctors and the cost of a health panic is more useful than another round of the argument.
Aug 22, 2026
